Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

June 17, 2024 7:25 AM EDT Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $55.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst commented: "Dyne ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login